Thursday Earnings: AZN, DEO, AAL

 | Jul 27, 2017 11:37AM ET

Equity Analysts are Thursday the ‘day from hell’ as 14 FTSE 100 companies report. Let’s take a look at the three most interesting charts from those we've heard from.h3 Astrazeneca (NYSE:AZN)/h3

‘Day of hell’ does not do justice for what we are seeing with AstraZeneca. The shares gapped 15% lower at the open and at the time of writing, prices were down over 16%. A close at this level would see over £1.3bln knocked off the company’s value — not a great day for management, to say the least.

First, we note that AZN’s Q2 results have taken a back seat today. This morning’s plummet lower is all about disastrous late stage trial results from AZN’s lung cancer drug, Imfinzi. The trial results showed that when using Imfinzi in combination with other drugs, patients fared worse than the control group which were treated with the standard platinum-based chemotherapy. Although management put a brave face on it, investors were less than impressed.

Looking at the price chart, we note that Thursday’s gap lower sees a decisive bearish break of a longer-term ‘ascending channel.’